MCL coexpression mm9:225

Phase1 CAGE Peaks

	Short description
Mm9::chr10:34822425..34822426,+	p@chr10:34822425..34822426 +
Mm9::chr12:8954768..8954786,+	p1@Matn3
Mm9::chr13:24247072..24247085,-	p6@Lrrc16a
Mm9::chr13:89680450..89680470,+	p1@Hapln1
Mm9::chr15:97806343..97806352,-	p@chr15:97806343..97806352 -
Mm9::chr15:97806491..97806499,-	p@chr15:97806491..97806499 -
Mm9::chr15:97806555..97806573,-	p@chr15:97806555..97806573 -
Mm9::chr15:97806587..97806603,-	p@chr15:97806587..97806603 -
Mm9::chr15:97807109..97807127,-	p@chr15:97807109..97807127 -
Mm9::chr15:97807155..97807166,-	p@chr15:97807155..97807166 -
Mm9::chr15:97807173..97807191,-	p@chr15:97807173..97807191 -
Mm9::chr15:97807229..97807247,-	p@chr15:97807229..97807247 -
Mm9::chr15:97807283..97807309,-	p@chr15:97807283..97807309 -
Mm9::chr15:97807708..97807732,-	p@chr15:97807708..97807732 -
Mm9::chr15:97808264..97808278,-	p@chr15:97808264..97808278 -
Mm9::chr15:97808333..97808351,-	p@chr15:97808333..97808351 -
Mm9::chr15:97835065..97835083,-	p1@Col2a1
Mm9::chr17:34176407..34176426,+	p1@Col11a2
Mm9::chr1:24184528..24184550,+	p2@Col9a1
Mm9::chr1:89366833..89366856,+	p1@3110079O15Rik
Mm9::chr1:89366868..89366879,+	p3@3110079O15Rik
Mm9::chr1:89366883..89366905,+	p2@3110079O15Rik
Mm9::chr2:29713767..29713788,+	p@chr2:29713767..29713788 +
Mm9::chr2:77459335..77459343,-	p@chr2:77459335..77459343 -
Mm9::chr3:113820930..113820931,+	p@chr3:113820930..113820931 +
Mm9::chr3:144955680..144955740,+	p1@Col24a1
Mm9::chr3:96449502..96449531,+	p1@Itga10
Mm9::chr4:130500292..130500306,+	p1@Matn1
Mm9::chr5:139882400..139882420,+	p2@C130050O18Rik
Mm9::chr7:86198101..86198120,+	p1@Acan
Mm9::chr7:86198122..86198151,+	p2@Acan
Mm9::chr7:86198174..86198187,+	p3@Acan
Mm9::chr7:86229411..86229424,+	p@chr7:86229411..86229424 +
Mm9::chr8:116941895..116941911,+	p1@Clec3a
Mm9::chr8:72897440..72897457,+	p1@Comp
Mm9::chr9:37476743..37476752,-	p2@Panx3
Mm9::chr9:37476755..37476811,-	p1@Panx3
Mm9::chrX:147261468..147261472,+	p1@ENSMUST00000145639

Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

---

GO ID	GO name	FDR corrected p-value
GO:0005578	proteinaceous extracellular matrix	9.94805947125308e-09
GO:0005201	extracellular matrix structural constituent	9.94805947125308e-09
GO:0022610	biological adhesion	4.72297215510633e-07
GO:0007155	cell adhesion	4.72297215510633e-07
GO:0030198	extracellular matrix organization and biogenesis	6.55853841387458e-07
GO:0044420	extracellular matrix part	3.81878223203534e-06
GO:0043062	extracellular structure organization and biogenesis	4.39897247315514e-06
GO:0030020	extracellular matrix structural constituent conferring tensile strength	7.75836238883046e-06
GO:0005581	collagen	1.23252054246797e-05
GO:0005518	collagen binding	6.5611849078916e-05
GO:0044421	extracellular region part	6.68622318005401e-05
GO:0006817	phosphate transport	6.68622318005401e-05
GO:0001502	cartilage condensation	0.000108032930554557
GO:0030199	collagen fibril organization	0.000233644177338014
GO:0005540	hyaluronic acid binding	0.000249129426871181
GO:0006029	proteoglycan metabolic process	0.000332456786598914
GO:0015698	inorganic anion transport	0.000429192999854446
GO:0006820	anion transport	0.000671512432102679
GO:0051216	cartilage development	0.00182731708572627
GO:0030246	carbohydrate binding	0.00238614933504166
GO:0005615	extracellular space	0.00306266264442543
GO:0005539	glycosaminoglycan binding	0.00374314072995
GO:0030247	polysaccharide binding	0.0042839181942941
GO:0001871	pattern binding	0.00451696322521827
GO:0001501	skeletal development	0.0189008761426242
GO:0005529	sugar binding	0.0193667460790394
GO:0016337	cell-cell adhesion	0.0231487892777975
GO:0006811	ion transport	0.0260616293747252
GO:0030166	proteoglycan biosynthetic process	0.0285255231838653
GO:0044262	cellular carbohydrate metabolic process	0.0292110437925668
GO:0009888	tissue development	0.0345915528954376
GO:0005921	gap junction	0.039418383839295
GO:0005975	carbohydrate metabolic process	0.0473343727651521

Relative expression of the co-expression cluster over median <br>Analyst:

---

Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>

---

Cell Type

Ontology term	p-value	n

Uber Anatomy

Ontology term	p-value	n

Disease

Ontology term	p-value	n

TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

---

Novel motifs

JASPAR motifs

Motifs	-log10(p-value)
{{{tfbs_overrepresentation_jaspar}}}